First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

被引：20

作者：

van Breeschoten, Jesper ^{[1
,2
]}

Wouters, Michel W. J. M. ^{[1
,3
]}

Hilarius, Doranne L. ^{[4
]}

Haanen, John B. ^{[5
]}

Blank, Christian U. ^{[5
,6
]}

Aarts, Maureen J. B. ^{[7
]}

van den Berkmortel, Franchette W. P. J. ^{[8
]}

de Groot, Jan-Willem B. ^{[9
]}

Hospers, Geke A. P. ^{[10
]}

Kapiteijn, Ellen ^{[11
]}

Piersma, Djura ^{[12
]}

van Rijn, Roos S. ^{[13
]}

Suijkerbuijk, Karijn P. M. ^{[14
]}

Blokx, Willeke A. M. ^{[15
]}

Tije, Bert-Jan J. ten ^{[16
]}

Veldt, Astrid A. M. van der ^{[17
,18
]}

Vreugdenhil, Art ^{[19
]}

Boers-Sonderen, Marye J. ^{[20
]}

van den Eertwegh, Alfonsus J. M. ^{[2
]}

机构：

[1] Dutch Inst Clin Auditing, Rijnsburgerweg 10, NL-2333 AA Leiden, Netherlands

[2] Vrije Univ Amsterdam Med Ctr, Canc Ctr Amsterdam, Amsterdam UMC, Dept Med Oncol, Boelelaan 1118, NL-1081 HZ Amsterdam, Netherlands

[3] Netherlands Canc Inst, Dept Surg Oncol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands

[4] Rode Kruis Ziekenhuis, Dept Pharm, Vondellaan 13, NL-1942LE Beverwijk, Netherlands

[5] Netherlands Canc Inst, Dept Med Oncol & Immunol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands

[6] Netherlands Canc Inst, Dept Mol Oncol & Immunol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands

[7] Maastricht Univ Med Ctr, Dept Med Oncol, P Debyelaan 25, NL-6229 HX Maastricht, Netherlands

[8] Zuyderland Med Ctr Sittard, Dept Med Oncol, Dr H van der Hoffpl 1, NL-6162BG Sittard Geleen, Netherlands

[9] Isala, Isala Oncol Ctr, Dokter Heesweg 2, NL-8025AB Zwolle, Netherlands

[10] Univ Med Ctr Groningen, Dept Med Oncol, Hanzepl 1, NL-9713GZ Groningen, Netherlands

[11] Leiden Univ, Dept Med Oncol, Med Ctr, Albinusdreef 2, NL-2333ZA Leiden, Netherlands

[12] Med Spectrum Twente, Dept Internal Med, Koningspl 1, NL-7512KZ Enschede, Netherlands

[13] Med Ctr Leeuwarden, Dept Internal Med, Henri Dunantweg 2, NL-8934AD Leeuwarden, Netherlands

[14] Univ Med Ctr Utrecht, Dept Med Oncol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands

[15] Univ Med Ctr Utrecht, Div Labs Pharm & Biomed Genet, Dept Pathol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands

[16] Amphia Hosp, Dept Internal Med, Molengracht 21, NL-4818CK Breda, Netherlands

[17] Erasmus MC, Dept Med Oncol & Radiol, S Gravendijkwal 230, NL-3015CE Rotterdam, Netherlands

[18] Erasmus MC, Dept Nucl Med, S Gravendijkwal 230, NL-3015CE Rotterdam, Netherlands

[19] Maxima Med Ctr, Dept Internal Med, De Run 4600, NL-5504DB Eindhoven, Netherlands

[20] Radboud Univ Nijmegen, Dept Med Oncol, Med Ctr, Geert Grootepl Zuid 10, NL-6525 GA Nijmegen, Netherlands

来源：

BRITISH JOURNAL OF CANCER | 2021年 / 124卷 / 07期

关键词：

METASTATIC MELANOMA; POOLED ANALYSIS; IPILIMUMAB; PEMBROLIZUMAB; VEMURAFENIB; DABRAFENIB; NIVOLUMAB; PHASE-3;

D O I：

10.1038/s41416-020-01229-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background Anti-PD-1 antibodies and BRAF/MEK inhibitors are the two main groups of systemic therapy in the treatment of BRAF(V600)-mutant advanced melanoma. Until now, data are inconclusive on which therapy to use as first-line treatment. The aim of this study was to use propensity score matching to compare first-line anti-PD-1 monotherapy vs. BRAF/MEK inhibitors in advanced BRAF(V600)-mutant melanoma patients. Methods We selected patients diagnosed between 2014 and 2017 with advanced melanoma and a known BRAF(V600)-mutation treated with first-line BRAF/MEK inhibitors or anti-PD-1 antibodies, registered in the Dutch Melanoma Treatment Registry. Patients were matched based on their propensity scores using the nearest neighbour and the optimal matching method. Results Between 2014 and 2017, a total of 330 and 254 advanced melanoma patients received BRAF/MEK inhibitors and anti-PD-1 monotherapy as first-line systemic therapy. In the matched cohort, patients receiving anti-PD-1 antibodies as a first-line treatment had a higher median and 2-year overall survival compared to patients treated with first-line BRAF/MEK inhibitors, 42.3 months (95% CI: 37.3-NE) vs. 19.8 months (95% CI: 16.7-24.3) and 85.4% (95% CI: 58.1-73.6) vs. 41.7% (95% CI: 34.2-51.0). Conclusions Our data suggest that in the matched BRAF(V600)-mutant advanced melanoma patients, anti-PD-1 monotherapy is the preferred first-line treatment in patients with relatively favourable patient and tumour characteristics.

引用

页码：1222 / 1230

页数：9

共 50 条

[1] First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis
Jesper van Breeschoten
Michel W. J. M. Wouters
Doranne L. Hilarius
John B. Haanen
Christian U. Blank
Maureen J. B. Aarts
Franchette W. P. J. van den Berkmortel
Jan-Willem B. de Groot
Geke A. P. Hospers
Ellen Kapiteijn
Djura Piersma
Roos S. van Rijn
Karijn P. M. Suijkerbuijk
Willeke A. M. Blokx
Bert-Jan J. ten Tije
Astrid A. M. van der Veldt
Art Vreugdenhil
Marye J. Boers-Sonderen
Alfonsus J. M. van den Eertwegh
British Journal of Cancer, 2021, 124 : 1222 - 1230
[2] Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis
Jesper van Breeschoten
Michel W. J. M. Wouters
Doranne L. Hilarius
John B. Haanen
Christian U. Blank
Maureen J. B. Aarts
Franchette W. P. J. van den Berkmortel
Jan-Willem B. de Groot
Geke A. P. Hospers
Ellen Kapiteijn
Djura Piersma
Roos S. van Rijn
Karijn P. M. Suijkerbuijk
Willeke A. M. Blokx
Bert-Jan J. ten Tije
Astrid A. M. van der Veldt
Art Vreugdenhil
Marye J. Boers-Sonderen
Alfonsus J. M. van den Eertwegh
British Journal of Cancer, 2022, 126 : 1362 - 1362
[3] First-line BRAF/MEK-inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: A propensity-matched survival analysis
Breeschoten, J. V.
Wouters, M.
Hilarius, D.
Haanen, J. B. A. G.
Blank, C. U.
Aarts, M.
Van den Berkmortel, F.
de Groot, J. W.
Hospers, G. A.
Kapiteijn, E.
Piersma, D.
Van Rijn, R.
Suijkerbuijk, K.
Blokx, W. A. M.
Ten Tije, A.
Van der Veldt, A. A. M.
Vreugdenhil, G.
Boers-Sonderen, M.
van den Eertwegh, A. J. M.
ANNALS OF ONCOLOGY, 2020, 31 : S1431 - S1431
[4] Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis
Jesper van Breeschoten
Michel W. J. M. Wouters
Doranne L. Hilarius
John B. Haanen
Christian U. Blank
Maureen J. B. Aarts
Franchette W. P. J. van den Berkmortel
Jan-Willem B. de Groot
Geke A. P. Hospers
Ellen Kapiteijn
Djura Piersma
Roos S. van Rijn
Karijn P. M. Suijkerbuijk
Willeke A. M. Blokx
Bert-Jan J. ten Tije
Astrid A. M. van der Veldt
Art Vreugdenhil
Marye J. Boers-Sonderen
Alfonsus J. M. van den Eertwegh
British Journal of Cancer, 2021, 124 : 1746 - 1746
[5] First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (vol 124, pg 1222, 2021)
van Breeschoten, Jesper
Wouters, Michel W. J. M.
Hilarius, Doranne L.
Haanen, John B.
Blank, Christian U.
Aarts, Maureen J. B.
van den Berkmortel, Franchette W. P. J.
de Groot, Jan-Willem B.
Hospers, Geke A. P.
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S.
Suijkerbuijk, Karijn P. M.
Blokx, Willeke A. M.
ten Tije, Bert-Jan J.
van der Veldt, Astrid A. M.
Vreugdenhil, Art
Boers-Sonderen, Marye J.
van den Eertwegh, Alfonsus J. M.
BRITISH JOURNAL OF CANCER, 2021, 124 (10) : 1746 - 1746
[6] First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis (Mar, 10.1038/s41416-022-01772-z, 2022)
van Breeschoten, Jesper
Wouters, Michel W. J. M.
Hilarius, Doranne L.
Haanen, John B.
Blank, Christian U.
Aarts, Maureen J. B.
van den Berkmortel, Franchette W. P. J.
de Groot, Jan-Willem B.
Hospers, Geke A. P.
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Roos S.
Suijkerbuijk, Karijn P. M.
Blokx, Willeke A. M.
ten Tije, Bert-Jan J.
van der Veldt, Astrid A. M.
Vreugdenhil, Art
Boers-Sonderen, Marye J.
van den Eertwegh, Alfonsus J. M.
BRITISH JOURNAL OF CANCER, 2022, 126 (09) : 1362 - 1362
[7] Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis
De Meza, Melissa M. M.
Blokx, Willeke A. M.
Bonenkamp, Johannes J. J.
Blank, Christian U. U.
Aarts, Maureen J. B.
van den Berkmortel, Franchette W. P. J.
Boers-Sonderen, Marye J. J.
De Groot, Jan Willem B.
Haanen, John B. A. G.
Hospers, Geke A. P.
Kapiteijn, Ellen
Van Not, Olivier J. J.
Piersma, Djura
Van Rijn, Rozemarijn S. S.
Stevense-den Boer, Marion
van der Veldt, Astrid A. M.
Vreugdenhil, Gerard
van den Eertwegh, Alfonsus J. M.
Suijkerbuijk, Karijn P. M.
Wouters, Michel W. J. M.
CANCERS, 2023, 15 (02)
[8] Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: Propensity score-matched recurrence-free, distant metastasis-free, and overall survival analysis
Bloem, Manja
de Meza, Melissa Melanie
Aarts, Maureen J. B.
Van den Berkmortel, Franchette
Blank, Christian U.
Blokx, Willeke
Boers-Sonderen, Marye J.
Bonenkamp, Han J.
de Groot, Jan Willem
Haanen, John
Hospers, Geke
Kapiteijn, Ellen
Piersma, Djura
van Rijn, Rozemarijn
Stevense-den Boer, Marion
Van der Veldt, Astrid Aplonia Maria
Vreugdenhil, Gerard
van den Eertwegh, Alfonsus Johannes Maria
Suijkerbuijk, Karijn
Wouters, Michel W. J. M.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[9] Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition
Johnson, Douglas B.
Pectasides, Eirini
Feld, Emily
Ye, Fei
Zhao, Shilin
Johnpulle, Romany
Merritt, Ryan
McDermott, David F.
Puzanov, Igor
Lawrence, Donald
Sosman, Jeffrey A.
Buchbinder, Elizabeth
Sullivan, Ryan J.
JOURNAL OF IMMUNOTHERAPY, 2017, 40 (01) : 31 - 35
[10] Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab
Moser, Justin C.
Chen, Danli
Hu-Lieskovan, Siwen
Grossmann, Kenneth F.
Patel, Shiven
Colonna, Sarah, V
Ying, Jian
Hyngstrom, John R.
CANCER MEDICINE, 2019, 8 (18): : 7637 - 7643

← 1 2 3 4 5 →